Primogene

Tucked inside Leipzig's growing deeptech ecosystem, Primogene is working on a problem that sits at the intersection of industrial chemistry and sustainability: how to produce complex biomolecules without the costly, polluting processes that have defined the sector for decades. The company's answer is enzymatic synthesis — a biologically inspired approach that replaces harsh chemical reactions with precision biochemical ones, producing high-value compounds more efficiently, more sustainably, and at a scale that makes commercial deployment viable. The molecules Primogene targets are not commodity chemicals. They are complex, high-margin compounds used in functional nutrition, personal care, and pharmaceutical ingredients — categories where purity, consistency, and traceability matter enormously to buyers. Traditional production routes for these molecules often involve multi-step chemical synthesis, toxic solvents, and significant energy inputs. They are expensive to run, difficult to scale, and increasingly scrutinized from a regulatory and environmental standpoint. Enzymatic synthesis sidesteps many of these constraints, offering a cleaner process with a smaller footprint and the potential to bring down production costs as the technology matures. Primogene's €4.1 million Seed round, led by HTGF and TGFS, gives the company the capital to do two things: scale production capacity and expand the portfolio of molecules it can synthesize. Both are necessary for turning a compelling scientific platform into a durable commercial business. The molecule library matters because it broadens the addressable market and reduces dependence on any single product line. The capacity investment matters because enzymatic processes, however elegant, must eventually compete on unit economics with incumbents that have decades of process optimization behind them. What makes Primogene a noteworthy example of European deeptech is the combination of solid intellectual property, genuine industrial capability, and a direct line to sustainability impact. This is not a company that has filed patents and is waiting for the world to catch up. It has a production process that works, a market that is actively looking for cleaner alternatives, and investors with the patience and domain expertise to back a company building something technically difficult. The chemistry industry's sustainability challenge is real, and the transition away from legacy processes will require exactly the kind of foundational innovation that Primogene represents.